The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 101-59-87
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Abdullaeva Sh.R.

Petrov National Cancer Research Center

Semiglazova T.Y.

N.N. Petrov National Medical Research Centre of Oncology;
I.I. Mechnikov North-West State Medical University

Artemyeva A.S.

N.N. Petrov National Medical Research Center for Oncology

Kudryashova T.I.

Petrov National Cancer Research Center

Filatova L.V.

Petrov National Cancer Research Center

Semiglazov V.V.

Petrov National Cancer Research Center;
Pavlov First St. Petersburg State Medical University

Krivorotko P.V.

Petrov National Cancer Research Center;
Mechnikov North-Western State Medical University

Semiglazov V.F.

Petrov National Cancer Research Center;
Mechnikov North-Western State Medical University

Poly(ADP-ribose) polymerase (PARP) inhibitors for BRCA-associated early triple-negative breast cancer: progress and future hopes

Authors:

Abdullaeva Sh.R., Semiglazova T.Y., Artemyeva A.S., Kudryashova T.I., Filatova L.V., Semiglazov V.V., Krivorotko P.V., Semiglazov V.F.

More about the authors

Journal: Medical Technologies. Assessment and Choice. 2024;(1): 91‑100

DOI: 10.17116/medtech20244601191

Views: 646

Downloaded: 3

Buy for 200₽
Contact the author
Table of contents

To cite this article:

Abdullaeva ShR, Semiglazova TY, Artemyeva AS, et al. . Poly(ADP-ribose) polymerase (PARP) inhibitors for BRCA-associated early triple-negative breast cancer: progress and future hopes. Medical Technologies. Assessment and Choice. 2024;(1):91‑100. (In Russ.)
https://doi.org/10.17116/medtech20244601191

Подписка 2025 (Medical Technologies. Assessment and Choice)
МСФ на ЯМ
Close metadata
Recommended articles:
Methodological aspe­cts of complex therapy of loca­lly adva­nced rectal cancer. P.A. Herzen Journal of Onco­logy. 2024;(3):20-26
Tumor infi­ltrating lymphocytes (TILs) in triple nega­tive breast cancer. Russian Journal of Archive of Pathology. 2024;(3):5-11
Immune checkpoint inhi­bitors as a component of perioperative therapy in patients with rese­ctable esophageal and cardioesophageal junction cancer. P.A. Herzen Journal of Onco­logy. 2024;(5):62-68

Poly (ADP-ribose) polymerase (PARP) inhibitors have been approved for the treatment of germline BRCA1/2-mutated metastatic breast cancer. BRCA-associated breast cancer is associated with younger age of patients, aggressive course and higher risk of recurrence. Mutations in the BRCA genes result in loss of function of BRCA proteins. The last ones are essential in DNA repair, cell cycle control and genomic stability. In these cells, repair of double-strand DNA breaks through homologous recombination is disrupted. As a consequence, tumors with mutations in the BRCA genes are highly sensitive to DNA-damaging agents, such as platinum agents and PARP inhibitors. The recent OlympiA trial has demonstrated better disease-free and overall survival after adjuvant therapy with olaparib in high-risk HER2-negative BRCA-associated early breast cancer (EBC). It is expected that PARP inhibitors will be valuable for the treatment of EBC. In this article, we review recent clinical data and ongoing trials, as well as discuss the prospects of PARP inhibitors.

Keywords:

PARP inhibitors
BRCA1/2
HRD
triple negative breast cancer
neoadjuvant therapy
platinum-based drugs
olaparib

Authors:

Abdullaeva Sh.R.

Petrov National Cancer Research Center

Semiglazova T.Y.

N.N. Petrov National Medical Research Centre of Oncology;
I.I. Mechnikov North-West State Medical University

Artemyeva A.S.

N.N. Petrov National Medical Research Center for Oncology

Kudryashova T.I.

Petrov National Cancer Research Center

Filatova L.V.

Petrov National Cancer Research Center

Semiglazov V.V.

Petrov National Cancer Research Center;
Pavlov First St. Petersburg State Medical University

Krivorotko P.V.

Petrov National Cancer Research Center;
Mechnikov North-Western State Medical University

Semiglazov V.F.

Petrov National Cancer Research Center;
Mechnikov North-Western State Medical University

Received:

23.10.2023

Accepted:

14.12.2023

List of references:

  1. Buys SS, Sandbach JF, Gammon A, Patel G, Kidds J, Brown KL, et al. A study of over 35,000 women with breast cancer tested with a 25-gene panel of hereditary cancer genes. Cancer. 2017;123(10):1721-1730. https://doi.org/10.1002/cncr.30498
  2. Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies [published correction appears in Am J Hum Genet. 2003;73(3):709]. American Journal of Human Genetics. 2003;72(5):1117-1130. https://doi.org/10.1086/375033
  3. Gudmundsdottir K, Ashworth A. The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability. Oncogene. 2006;25(43):5864-5874. https://doi.org/10.1038/sj.onc.1209874
  4. Rebbeck TR, Friebel TM, Friedman E, Hamman U, Huo D, Kwong A, et al. Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations. Human Mutation. 2018;39(5):593-620.  https://doi.org/10.1002/humu.23406
  5. Sokolenko AP, Rozanov ME, Mitiushkina NV, Sherina NYu, Iyevleva AG, Chekmariova EV, et al. Founder mutations in early-onset, familial and bilateral breast cancer patients from Russia. Familial Cancer. 2007;6(3):281-286.  https://doi.org/10.1007/s10689-007-9120-5
  6. Imyanitov EN, Hereditary breast cancer. Prakticheskaya onkologiya. 2010;11(4):258-266. (In Russ.).
  7. Imyanitov EN, Filipenko ML, Kekeyeva TV, Demidova IA, Practical aspects of BRCA1/2 testing: position of the Russian society of molecular geneticists in oncology and oncohematolog. Voprosy onkologii. 2022;68(3):260-266. (In Russ.). https://doi.org/10.37469/0507-3758-2022-68-3-260-266
  8. Foulkes WD, Stefansson IM, Chappuis PO, Bégin LR, Goffin GR, Wong N, et al. Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. Journal of the National Cancer Institute. 2003;95(19):1482-1485. https://doi.org/10.1093/jnci/djg050
  9. Brekelmans CT, Tilanus-Linthorst MM, Seynaeve C, Ouweland A, Menke-Pluymers MBE, Bartels CCM, et al. Tumour characteristics, survival and prognostic factors of hereditary breast cancer from BRCA2-, BRCA1- and non-BRCA1/2 families as compared to sporadic breast cancer cases. European Journal of Cancer. 2007;43(5):867-876.  https://doi.org/10.1016/j.ejca.2006.12.009
  10. Farmer H, McCabe N, Lord CJ, Tutt ANJ, Johnson DA, Richardson TB, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005;434(7035):917-921.  https://doi.org/10.1038/nature03445
  11. Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly (ADP-ribose) polymerase [published correction appears in Nature. 2007;447(7142):346]. Nature. 2005;434(7035):913-917.  https://doi.org/10.1038/nature03443
  12. Chai Y, Chen Y, Zhang D, Wei Yu, Li Zh, LiQ, et al. Homologous Recombination Deficiency (HRD) and BRCA 1/2 Gene Mutation for Predicting the Effect of Platinum-Based Neoadjuvant Chemotherapy of Early-Stage Triple-Negative Breast Cancer (TNBC): A Systematic Review and Meta-Analysis. Journal of Personalized Medicine. 2022;12(2):323.  https://doi.org/10.3390/jpm12020323
  13. Ashworth A. A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. Journal of Clinical Oncology. 2008;26(22):3785-3790. https://doi.org/10.1200/JCO.2008.16.0812
  14. Robson M, Im SA, Senkus E, Xu B, Domchek SM, Masuda N, et al. Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation [published correction appears in N Engl J Med. 2017;377(17):1700]. New England Journal of Medicine. 2017;377(6):523-533.  https://doi.org/10.1056/NEJMoa1706450
  15. Litton JK, Rugo HS, Ettl J, Hurvitz SA, Gonçalves A, Lee K-H, et al. Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation. New England Journal of Medicine. 2018;379(8):753-763.  https://doi.org/10.1056/NEJMoa1802905
  16. Robson ME, Tung N, Conte P, et al. OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Annals of Oncology. 2019;30(4):558-566.  https://doi.org/10.1093/annonc/mdz012
  17. Litton JK, Hurvitz SA, Mina LA, Rugo HS, Lee K-H, Gonçalves A, et al. Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial. Annals of Oncology. 2020;31(11):1526-1535. https://doi.org/10.1016/j.annonc.2020.08.2098
  18. Stoppa-Lyonnet D. The biological effects and clinical implications of BRCA mutations: where do we go from here? European Journal of Human Genetics. 2016;24(suppl 1):S3-S9.  https://doi.org/10.1038/ejhg.2016.93
  19. Imyanitov EN, Protsenko SA, Semiglazova TYu. Opportunities for antitumor drugs replacemen. Voprosy onkologii. 2022;68(6):833-838. (In Russ.). https://doi.org/10.37469/0507-3758-2022-68-6-833-838
  20. Blum JL, Flynn PJ, Yothers G, Asmar L, Geyer CE Jr, Jacobs SA, et al. Anthracyclines in Early Breast Cancer: The ABC Trials-USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology). Journal of Clinical Oncology. 2017;35(23):2647-2655. https://doi.org/10.1200/JCO.2016.71.4147
  21. von Minckwitz G, Schneeweiss A, Loibl S, Salat C, Denkert C, Rezai M, et al. Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. Lancet Oncology. 2014;15(7):747-756.  https://doi.org/10.1016/S1470-2045(14)70160-3
  22. Sikov WM, Berry DA, Perou CM, Singh B, Cirrincione CT, Tolaney SM, et al. Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). Journal of Clinical Oncology. 2015;33(1):13-21.  https://doi.org/10.1200/JCO.2014.57.0572
  23. Loibl S, O’Shaughnessy J, Untch M, Sikov WM, Rugo HS, McKee MD, et al. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial. Lancet Oncology. 2018;19(4):497-509.  https://doi.org/10.1016/S1470-2045(18)30111-6
  24. Poggio F, Bruzzone M, Ceppi M, Pondé NF, La Valle G, Del Mastro L, et al. Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis. Annals of Oncology. 2018;29(7):1497-1508. https://doi.org/10.1093/annonc/mdy127
  25. Gradishar WJ, Moran MS, Abraham J, Aft B, Agnese D, Allison KH, et al. Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network. 2022;20(6):691-722.  https://doi.org/10.6004/jnccn.2022.0030
  26. Tamirisa N, Hunt KK. Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline. Annals of Surgical Oncology. 2022;29(3):1489-1492. https://doi.org/10.1245/s10434-021-11223-3
  27. Caramelo O, Silva C, Caramelo F, Frutuoso C, Almeida-Santos T. The effect of neoadjuvant platinum-based chemotherapy in BRCA mutated triple negative breast cancers-systematic review and meta-analysis. Hereditary Cancer in Clinical Practice. 2019;17:11.  https://doi.org/10.1186/s13053-019-0111-y
  28. Hahnen E, Lederer B, Hauke J, et al. Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer: Secondary Analysis of the GeparSixto Randomized Clinical Trial. JAMA Oncology. 2017;3(10):1378-1385. https://doi.org/10.1001/jamaoncol.2017.1007
  29. Schmid P, Cortes J, Pusztai L, McArthur H, Kümmel Sh, Bergh J, et al. Pembrolizumab for Early Triple-Negative Breast Cancer. New England Journal of Medicine. 2020;382(9):810-821.  https://doi.org/10.1056/NEJMoa1910549
  30. Donawho CK, Luo Y, Luo Y, Penning TD, Bauch JL, Bouska JJ, et al. ABT-888, an orally active poly (ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clinical Cancer Research. 2007;13(9):2728-2737. https://doi.org/10.1158/1078-0432.CCR-06-3039
  31. Fasching PA, Link T, Hauke J, et al. Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study). Annals of Oncology. 2021;32(1):49-57.  https://doi.org/10.1016/j.annonc.2020.10.471
  32. Fasching PA, Schmatloch S, Hauke J, Seither F, Jackisch C, Klare P, et al. Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency — long-term survival of the GeparOLA study. Abstract GS5-02. Presented at 2022 San Antonio Breast Cancer Symposium; December 6-10, 2022. San Antonio, TX; 2022.
  33. Alba KP, McMurtry E, Vallier A-L, Grybowicz L, Copson E, Armstrong A, et al. Abstract P3-10-05: Preliminary safety data from stage 1 and 2 of the phase II/III PARTNER trial: Addition of olaparib to platinum-based neoadjuvant chemotherapy in triple negative and/or germline BRCA mutated breast cancer patients. Cancer Research. 2020;80:P3-10-05.  https://doi.org/10.1158/1538-7445.SABCS19-P3-10-05
  34. Nanda R, Liu MC, Yau C, Shatsky R, Pusztai L, Wallace A, et al. Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial. JAMA Oncology. 2020;6(5):676-684.  https://doi.org/10.1001/jamaoncol.2019.6650
  35. Rugo HS, Olopade OI, DeMichele A, Shatsky R, Pusztai L, Wallace A, et al. Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer. New England Journal of Medicine. 2016;375(1):23-34.  https://doi.org/10.1056/NEJMoa1513749
  36. Litton JK, Scoggins ME, Hess KR, Adrada B, Murthy RK, Senthil Damodaran S, et al. Neoadjuvant Talazoparib for Patients With Operable Breast Cancer With a Germline BRCA Pathogenic Variant. Journal of Clinical Oncology. 2020;38(5):388-394.  https://doi.org/10.1200/JCO.19.01304
  37. Litton JK, Beck JT, Jones JM, Andersen J, Blum JL, Mina LA, et al. Neoadjuvant talazoparib in patients with germline BRCA1/2 (gBRCA1/2) mutation-positive, early HER2-negative breast cancer (BC): results of a phase 2 study. Journal of Clinical Oncology. 2021;28:505.  https://doi.org/10.1093/oncolo/oyad139
  38. Eikesdal HP, Yndestad S, Elzawahry A, Llop-Guevara A, Gilje B, Blix ES, et al. Olaparib monotherapy as primary treatment in unselected triple negative breast cancer. Annals of Oncology. 2021;32(2):240-249.  https://doi.org/10.1016/j.annonc.2020.11.009
  39. Spring LM, Han H, Liu MC, Hamilton E, Irie H, Santa-Maria CA, et al. Neoadjuvant study of niraparib in patients with HER2-negative, BRCA-mutated, resectable breast cancer [published correction appears in Nat Cancer. 2022 Aug 5]. Nature Reviews Cancer. 2022;3(8):927-931.  https://doi.org/10.1038/s43018-022-00400-2
  40. Tutt ANJ, Garber JE, Kaufman B, Viale G, Fumagalli D, Rastogi P, et al.; OlympiA Clinical Trial Steering Committee and Investigators. Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer. New England Journal of Medicine. 2021;384(25):2394-2405. https://doi.org/10.1056/NEJMoa2105215
  41. Geyer CE Jr, Garber JE, Gelber RD, Yothers G, Taboada M, Ross L, et al.; OlympiA Clinical Trial Steering Committee and Investigators. Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer. Annals of Oncology. 2022;33(12):1250-1268. https://doi.org/10.1016/j.annonc.2022.09.159
  42. Miller K, Tong Y, Jones DR, Walsh T, Danso MA, Ma CX, et al. Cisplatin with or without rucaparib after preoperative chemotherapy in patients with triple negative breast cancer: Final efficacy results of Hoosier Oncology Group BRE09-146. Journal of Clinical Oncology. 2015;33:1082-1082. https://doi.org/10.1200/jco.2015.33.15_suppl.1082
  43. Jannetti SA, Zeglis BM, Zalutsky MR, Reiner T. Poly (ADP-Ribose) Polymerase (PARP) Inhibitors and Radiation Therapy. Frontiers in Pharmacology. 2020;11:170.  https://doi.org/10.3389/fphar.2020.00170
  44. Michmerhuizen AR, Pesch AM, Moubadder L, Chandler BC, Wilder-Romans K, Cameron M, et al. PARP1 Inhibition Radiosensitizes Models of Inflammatory Breast Cancer to Ionizing Radiation. Molecular Cancer Therapeutics. 2019;18(11):2063-2073. https://doi.org/10.1158/1535-7163.MCT-19-0520
  45. Feng FY, Speers C, Liu M, Jackson WC, Moon D, Rinkinen J, et al. Targeted radiosensitization with PARP1 inhibition: optimization of therapy and identification of biomarkers of response in breast cancer. Breast Cancer Research and Treatment. 2014;147(1):81-94.  https://doi.org/10.1007/s10549-014-3085-5
  46. Zhao W, Hu H, Mo Q, Guan Y, Li Y, Du Y, et al. Function and mechanism of combined PARP-1 and BRCA genes in regulating the radiosensitivity of breast cancer cells. International Journal of Clinical and Experimental Pathology. 2019;12(10):3915-3920.
  47. Vinayak S, Tolaney SM, Schwartzberg L, Mita M, McCann G, Tan AR, et al. Open-label Clinical Trial of Niraparib Combined with Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer. JAMA Oncology. 2019;5(8):1132-1140. https://doi.org/10.1001/jamaoncol.2019.1029
  48. Grandal B, Evrevin C, Laas E, Jardin I, Rozette S, Laot L, et al. Impact of Mutation Status on Tumor Infiltrating Lymphocytes (TILs), Response to Treatment, and Prognosis in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy. Cancers (Basel). 2020;12(12):3681. https://doi.org/10.3390/cancers12123681
  49. de Boo L, Cimino-Mathews A, Lubeck Y, Daletzakis A, Opdam M, Sanders J, et al. Tumour-infiltrating lymphocytes (TILs) and BRCA-like status in stage III breast cancer patients randomised to adjuvant intensified platinum-based chemotherapy versus conventional chemotherapy. European Journal of Cancer. 2020;127:240-250.  https://doi.org/10.1016/j.ejca.2019.12.003
  50. Mouw KW, Goldberg MS, Konstantinopoulos PA, D’Andrea AD. DNA Damage and Repair Biomarkers of Immunotherapy Response. Cancer Discovery. 2017;7(7):675-693.  https://doi.org/10.1158/2159-8290.CD-17-0226
  51. Perakis S, Speicher MR. Emerging concepts in liquid biopsies. BMC Medicine. 2017;15(1):75.  https://doi.org/10.1186/s12916-017-0840-6
  52. Russo M, Bardelli A. Lesion-Directed Therapies and Monitoring Tumor Evolution Using Liquid Biopsies. Cold Spring Harbor Perspectives in Medicine. 2017;7(2):a029587. https://doi.org/10.1101/cshperspect.a029587
  53. Lord CJ, Ashworth A. BRCAness revisited. Nature Reviews Cancer. 2016;16(2):110-120.  https://doi.org/10.1038/nrc.2015.21
  54. Tung NM, Robson ME, Ventz S, Santa-Maria CA, Nanda R, Marcom PK, et al. TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes. Journal of Clinical Oncology. 2020;38(36):4274-4282. https://doi.org/10.1200/JCO.20.02151

Close metadata

Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register


We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.